Baldrige Asset Management’s Definium Therapeutics DFTX Stock Holding History

Baldrige Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$0	Hold	133	–	–	﹤0.01%	441
2022 Q4	$0	Hold	133	–	–	﹤0.01%	321
2022 Q3	$0	Hold	133	–	–	﹤0.01%	305
2022 Q2	$1K	Hold	133	–	–	﹤0.01%	296
2022 Q1	$2K	Hold	133	–	–	﹤0.01%	295
2021 Q4	$3K	Hold	133	–	–	﹤0.01%	303
2021 Q3	$5K	Hold	133	–	–	﹤0.01%	316
2021 Q2	$7K	Buy	+133	New	+$6.98K	﹤0.01%	312

Other funds holding DFTX

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Baldrige Asset Management's DFTX Position: Q1 2023 in Review

Baldrige Asset Management held its Definium Therapeutics (DFTX) position steady in Q1 2023 at 133 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #441.

Baldrige Asset Management first reported a position in DFTX in Q2 2021 and has held it in 8 quarters since. The position peaked at $7K in Q2 2021. 88 funds tracked by Wall St. Rank hold DFTX as of Q1 2023.

Baldrige Asset Management held 133 shares of Definium Therapeutics worth $0 as of Q1 2023.
Baldrige Asset Management left its Definium Therapeutics share count unchanged in Q1 2023.
Definium Therapeutics made up ﹤0.01% of Baldrige Asset Management's portfolio in Q1 2023, its #441 holding.
Baldrige Asset Management first reported a position in Definium Therapeutics in Q2 2021 and has held it in 8 quarters since.
Baldrige Asset Management's Definium Therapeutics position peaked at $7K in Q2 2021.
88 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2023.

Based on Baldrige Asset Management's 13F filing for Q1 2023, filed 17 Apr 2023.